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Summary Successful treatment of ocular tumours by chemotherapy and radiotherapy is sometimes limited
by the special nature of the eye. Improvement is needed to avoid enucleation. Previous studies using locally
administered antineoplastic agents have given promising results in the treatment of experimental ocular
melanoma and spontaneous lymphoma. Another approach is use of radiosensitizers to improve
radiotherapeutic effect.
For the present study, 5-thio-D-glucose and cis-platin were chosen for evaluation in an ocular system
because they exhibit antitumour activity, and interaction with radiation, particularly in hypoxia. Ocular
absorption, toxicity, and pharmacokinetics after subconjunctival administration in rabbits were determined,
and the effect of drug on tumours was measured using a Greene melanoma model. CHO cells were used for
complimentary in vitro studies.
5-thio-D-glucose was readily absorbed into the eye (300 mg resulting in 5 mm in the aqueous) with no
observable toxicity. When STG (300mg) was administered at implantation, tumours were approximately half
the size of controls. 5 mM 5TG is toxic to extremely hypoxic cells and gives measurable radiosensitization.
Cis-platin levels as high as 0.68 gM were attained in the aqueous without local toxicity after 400 jg injection.
This concentration causes toxicity in vitro. Cis-platin (400mg) had a larger effect on tumour growth than
5TG given at, or one week after, implantation. Cis-platin may have potential for treatment of ocular tumours
by local injection.
Ocular tumours present special problems in management due
to sensitivity of the eye and its relative pharmacological
isolation. Melanoma and retinoblastoma are the most
common primary tumours in this location and the incidence
of metastatic spread of solid tumours to the eye is
increasing. There is considerable effort towards improve-
ments in local control of disease by non-surgical methods.
Chemotherapy and radiotherapy, the alternative methods of
treatment, are not without complications. Local administra-
tion of antineoplastic drugs to the eye is being evaluated
by us as a means of penetrating this pharmacological
sanctuary. Absorption and pharmacokinetics after local
administration of antineoplastic agents have been compared
with the i.v. route in the rabbit eye (e.g. Rootman et al.,
1983b; Rootman et al., 1984). Effects on melanoma in
rabbits (Rootman et al., submitted), ocular leukaemia in
humans (Rootman & Gudauskas, 1981) and lymphosarcoma
in a cat (Rootman et al., 1983a) encourage further investi-
gation of this direct route of administration. Related studies
on absorption of nitroimidazole radiosensitizers were carried
out (Rootman et al., 1982) because of their possible use in
treatment of retinoblastoma, which contains hypoxic cells
(Gallie et al., 1982). Here, we examine drugs which may have
both direct toxicity to, and/or increased radiosensitivity of,
the resistant hypoxic fraction in tumours. For the initial
study on tumoricidal effects, an implantable ocular
melanoma described by Greene and Harvey (1966) was used
to examine the following drugs:
(i) 5-thio-D-glucose - selected (Skov et al., 1984) because
of its antitumour activity (Bushway & Whistler, 1975);
low systemic toxicity (LD50 -5.5gkg-1) (Song et al.,
1986); toxicity to and radiosensitization of hypoxic
cells (Song et al., 1978, 1980) and tumours (Markoe
et al., 1980); protection of oxygenated (normal) cells
against radiation damage (Schuman et al., 1982); and
high uptake in animal tumour (Markoe et al., 1980b).
The direct action of 5TG is presumed due to inter-
ference with glucose metabolism and the interaction
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with radiation may be due to resulting interference
with repair of DNA damage (Nagle et al., 1980).
(ii) Cis-platin - a successful antineoplastic agent which
potentiates radiation damage in hypoxia (Douple &
Richmond, 1979; Nias, 1985). This interaction which
is being exploited clinically (Coughlin et al., 1984) is
not understood but may be due to DNA binding.
Materials and methods
Ocular toxicity studies
The drugs, 5TG (Sigma Chemical Corporation, St. Louis):
100, 200, 300, 400mg; and cis-platin (David Bull Labora-
tories, Victoria, Australia): 50, 100, 200, 300, 400, 500,ug
were administered subconjunctivally in 0.5ml saline to the
eye of 5-7 groups of 2 rabbits (locally supplied white New
Zealand females, 2.2-2.4kg), to establish tolerance. Periodic
slit lamp examination, photography and histopathology were
used to determine the maximum tolerable doses: 300mg for
5TG and 400,ug for cis-platin.
Ocular absorption studies
For each drug, 6 groups of 3 rabbits were tranquillized by
im. injection of ketamine/acepromazine maleate (Rogar
STB/Ayerst) (100mgml-'; 10:1; -0.2mlkg-10.5h-1) and
the drug was injected subconjunctivally posterior to the
superior limbus of the r-ight eye using a 30 gauge needle.
Blood samples were obtained in heparinized syringes at 0.5,
1, 2, 4, 8, and 12h by intermittent puncture of the medial
artery of the right ear. The samples were centrifuged and the
plasma collected. Urine was continuously collected and
volumes recorded. A volume of about 0.1 ml aqueous fluid
was obtained by means of anterior chamber paracentesis, the
eye was then enucleated, cleaned, rinsed with saline, and the
vitreous was expressed. For 5TG absorption, purified
uniformly tritiated 5TG (prepared by Amersham/Searle) was
mixed with unlabelled drug to provide a dose of 300mg with
30 x 106 dpm; 50,ul aqueous samples and 100,ul samples from
serum, urine and vitreous were counted in PCS (phase
combining system - Amersham/Searle) on a Beckman L.S.C.
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5800 using a wide open tritium window. Cis-platin uptake
was measured in similar samples after 400pg injection using
atomic absorption (Perkin-Elmer with graphite furnace,
Varian lamp 265.9 pm with program; dry 120°C 40", ash
1400°C 30", atomize 2500°C 7").
Tumour studies - Implantation, treatment and assessment
An amelanotic variant of a spontaneous hamster melanoma
(Greene & Harvey, 1966) which had been carried in serial
transplantation in the anterior chambers of rabbits was
harvested by enucleation and dissection of gross tumour and
pressed through a fine mesh sieve to release and separate
cells. The cells were suspended in medium (RPMI 1640
Terry Fox Laboratory with 20% foetal calf serum), washed
twice with PBS and resuspended in normal saline. The
viability of cells was checked by means of trypan blue stain
and the concentration was adjusted to 1 x 106 viable cells in
0.2ml for injection. The anterior chamber of the right eye
was evacuated by tapping the aqueous fluid through the
limbus with a 27 gauge needle, and 0.2ml of tumour
suspension was injected.
Rabbits were divided into 3 groups of 3 or 4 animals each:
Group 1 received injection of drugs starting immediately
after tumour implantation: (300mg 5TG or 400pg cis-platin
in saline); Group 2 received the same subconjunctival
injection of 5TG or cis-platin one week after the tumour
implantation; Group 3 received saline and served as controls.
Drugs were given twice a week for 17 days. Daily ocular
examinations using a slit lamp were performed to monitor
tumour growth. At the end of the experiment (17th day), the
animals were sacrificed, eyes weighed and prepared for
histological sectioning. Effectiveness of treatment was deter-
mined by comparison of weight of tumour in the treated
groups with the control groups. These results were supported
by histopathological means, and by photography to evaluate
the size and extent of tumour invasion in the eye.
In vitro experiments
CHO cells were used to study the toxicity and radiosensi-
tizing ability of 5TG and cis-platin under hypoxic and oxic
conditions. Radiobiological hypoxia is produced by flow of
nitrogen for 30-45min over stirred suspension of cells. The
methods used in this laboratory routinely (Moore et al.,
1976) result in standard OER (2.8), hypoxic toxicity of
misonidazole, etc.; however, to see toxicity of 5TG in
hypoxic cells, higher cell densities (106ml-1) and/or incu-
bation at 37°C was required to ensure a more complete
depletion of oxygen than is needed in radiobiology (Schultz
& Bongiorni, 1984). Cis-platin on the other hand gives
reproducible marked toxicity in both oxic and hypoxic cells
under our standard conditions.
Results and discussion
Toxicity and absorption
5TG caused no severe reactions at relatively high doses and
it was felt that repeated local administration of this drug
would be possible. A dose of 400mg in 0.5ml was not
exceeded due to solubility/viscosity of the drug. At this
upper dose, the main clinical signs of toxicity were extreme
conjunctival oedema and slight conjunctival hyperemia with
moderate flare and cells in the anterior chambers. The
maximum tolerable dose, 300mg in 0.5ml resulted in a peak
concentration in the right aqueous of 5mm at approximately
one hour (Figure la), with some absorption into the right
vitreous, and into the left eye due to crossover. Relative bio-
availabilities over 12h for 5TG was 1,122 gh-1 and
244pgh-1 for the right and left anterior chambers respec-
tively. 5TG clearance via body fluids is shown in Figure 2a.
In vitro, considerable toxicity at this concentration can be
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Figure 1 (a) Concentration of 5-thio-D-glucose in vitreous
(right eye, A A; left eye, A- -A) and anterior chamber
(right eye, O El; left eye, * *) following 300mg sub-
conjunctival injection. (b) Concentration of cis-platin in right
(Ol [l) and left (U U) anterior chambers following
400pg subconjunctival injection (Vitreous below limit of
detection).
The left eye (control) shows some absorption due to crossover
from the injected (right) eye.
measured in extremely hypoxic cells (Schultz & Bongiorni,
1984). In CHO cells, we found a plating efficiency of 10-3 at
8h which is more than observed in radiobiological hypoxia
(Song et al., 1977, 1978). Slight radiosensitization (E.R. -
1.1) was produced by this concentration of 5TG in extremely
hypoxic CHO cells.
The maximum tolerable dose of cis-platin was 400,pg in
0.5ml which resulted in a peak concentration of 0.68,pM in
the right aqueous at 0.5h (Figure lb). Levels in the vitreous
were below detection limits (0.04pM). Bio-availabilities over
12h for cis-platin were 0.17gh-1 and 0.06pgh-1 for the
right and left anterior chambers respectively. Platinum
elimination is shown in Figure 2b. When the maximum
tolerated doses of cis-platin were exceeded (500,pg, the
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Figure 3 Effect of drugs on growth of ocular melanoma. 300mg
of 5TG (twice weekly) or 400pg of cis-platin (c-Pt) (twice
weekly) commencing at time of implantation (group 1) or at I
week (group 2). Controls received saline only.
the degree of hypoxia. A measurable direct effect of 5TG in
ocular melanoma is suggested by our experiments: this needs
further characterization.
Cis-platin showed a greater effect on tumour growth than
5TG, with an average tumour weight of 0.15 g when drug
I \^_ was started at time of implantation (0.8 g for 5TG) or 0.94g
_ | ~ when treatment was initiated one week after tumour implan-
tation (1.7 g for 5TG) compared with 2.0g for control
animals. This response encourages further investigation of
- platinum for this system. Experiments using second
generation platinum drugs undergoing clinical trials are
planned; combinations with other drugs which inhibit
tumour growth, e.g. 5-fluorouracil (Rootman et al.,
I 'I I . submitted) will be assessed; and tumour levels will be
2 4 6 8 10 12 measured.
Time (hours) Ocular tumours, while presenting specific difficult
challenges to the clinician, offer certain advantages to the
2 Serum and urinary profiles of drugs administered to researcher. Their growth can be monitored visually and
;s eye as in Figure 1, determined using tritiated 5TG or assessed during treatment, at least in a qualitative manner.
c absorption (Pt). (a) 5TG; (b) Pt. A A, urine; Local injection of various types of drug may prove to be the
-A, serum. route of administration of choice for ocular disease. As well
as minimizing systemic toxicity, local administration might
have additional advantages over systemic administration for ctiva became oedematous and hyperemic wlth a disease such as retinoblastoma, where second primary
atsfand thaemorehage Tegoreayecells he neoplasms are frequent which may be related to treatment
atous and there was moderate flare and cells in the by drugs or radiotherapy (Draper et al., 1986). In addition,
r chamber in vtO teris a ble sht this route of administration offers the opportunity to ir-
y(oxic or hypoxic CHO cells) at 0.5 to 1 pM. The radiate when radiosensitizer concentration is maximum
tion with radiation is not measureable at this low level (Figue 1). retioblasitom contansrhypoxic s (axieue
'he standard cloning assay. ~(Figure 1). Retinoblastoma contains hypoxic cells (Gallie et
al., 1982) which are believed responsible, at least in part, for
ofdrugs on Greene melanoma the failure of local control. Melanoma is reputed to be
radioresistant, although this may need reassessment
ntrol animals, the tumour grew rapidly: nodules (Harwood & Cummings, 1981). Further evaluation of ocular
*ed on the iris at -day 5, neovascularization and a melanoma for radiobiological studies is warranted and
ied iris at -day 10, with perforation at the limbus at further studies of the interactions between drugs and
17. The tumour filled the anterior chamber and large radiation is planned using retinoblastoma and uveal
)f necrosis were observed. melanoma cells in vitro.
Tumours in the eyes of rabbits treated locally with 5TG
commencing at the time of implantation were approximately
half the size of controls (Figure 3); those whose treatment
began after one week did not show significant growth delay.
Some authors have seen an effect of 5TG on tumours
(Markoe et al., 1980b; Song et al., 1980), yet others found no
effect (Rockwell & Schultz, 1984; Tannock et al., 1983). 5TG
effectiveness may depend on the site, the detailed metabolic
pathways of the tumour cell, the concentration attained and
Supported by the B.C. Health Care Research Foundation, Medical
Research Council of Canada and the B.C. Cancer Foundation. M.O.
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